Literature DB >> 2369797

Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes.

S Batra1.   

Abstract

The interaction of tamoxifen and clomifene with membrane binding sites for the cholinergic ligand quinuclidinyl benzilate (QNB) and the dihydropyridine calcium antagonist nitrendipine was studied. Both tamoxifen and clomifene competed with [3H]-QNB and [3H]-nitrendipine for their binding to the receptor in the membrane fractions from the urinary bladder and myometrium. The extent of inhibition as judged by the Ki values for both antiestrogens was similar at both receptor sites. The data suggest that the antiproliferative effects of tamoxifen may involve not only the intracellular estrogen-receptor system but also receptors for neurotransmitters and membrane calcium channels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369797     DOI: 10.1007/bf02897237

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Characterization of membrane calcium channels in nonpregnant and pregnant human uterus.

Authors:  S C Batra; L D Popper
Journal:  Gynecol Obstet Invest       Date:  1989       Impact factor: 2.031

2.  Comparison of muscarinic acetylcholine binding in the urinary bladder and submandibular gland of the rabbit.

Authors:  S Batra
Journal:  Eur J Pharmacol       Date:  1987-06-12       Impact factor: 4.432

3.  8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer.

Authors:  M E Lippman; R B Dickson; S Bates; C Knabbe; K Huff; S Swain; M McManaway; D Bronzert; A Kasid; E P Gelmann
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

4.  Exocrine secretion of epidermal growth factor by the rat prostate: effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide.

Authors:  S C Jacobs; M T Story
Journal:  Prostate       Date:  1988       Impact factor: 4.104

5.  Evidence that tamoxifen is a histamine antagonist.

Authors:  E A Kroeger; L J Brandes
Journal:  Biochem Biophys Res Commun       Date:  1985-09-16       Impact factor: 3.575

6.  Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene.

Authors:  C K Watts; L C Murphy; R L Sutherland
Journal:  J Biol Chem       Date:  1984-04-10       Impact factor: 5.157

7.  Calcium: calmodulin and cancer.

Authors:  W E Criss; S Kakiuchi
Journal:  Fed Proc       Date:  1982-05

8.  Calcium channel blockers: potential antimetastatic agents.

Authors:  K V Honn; J M Onoda; C A Diglio; B F Sloane
Journal:  Proc Soc Exp Biol Med       Date:  1983-10

9.  In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy.

Authors:  H M Runge; G Teufel; J Neulen; H Geyer; A Pfleiderer
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

Authors:  D G Bratherton; C H Brown; R Buchanan; V Hall; E M Kingsley Pillers; T K Wheeler; C J Williams
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

View more
  3 in total

1.  Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey.

Authors:  Susan A Hall; Gretchen R Chiu; David W Kaufman; Gary A Wittert; Carol L Link; John B McKinlay
Journal:  BJU Int       Date:  2011-09-27       Impact factor: 5.588

2.  Tamoxifen inhibits acidification in cells independent of the estrogen receptor.

Authors:  N Altan; Y Chen; M Schindler; S M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  Effects of anti-oestrogens and beta-estradiol on calcium uptake by cardiac sarcoplasmic reticulum.

Authors:  M L Dodds; M E Kargacin; G J Kargacin
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.